Esperion Therapeutics (ESPR) Competitors $1.19 -0.05 (-4.03%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.20 +0.01 (+0.42%) As of 07/11/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ESPR vs. SION, QURE, AVBP, CRON, XERS, PHAR, REPL, VIR, GYRE, and PHATShould you be buying Esperion Therapeutics stock or one of its competitors? The main competitors of Esperion Therapeutics include Sionna Therapeutics (SION), uniQure (QURE), ArriVent BioPharma (AVBP), Cronos Group (CRON), Xeris Biopharma (XERS), Pharming Group (PHAR), Replimune Group (REPL), Vir Biotechnology (VIR), Gyre Therapeutics (GYRE), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. Esperion Therapeutics vs. Its Competitors Sionna Therapeutics uniQure ArriVent BioPharma Cronos Group Xeris Biopharma Pharming Group Replimune Group Vir Biotechnology Gyre Therapeutics Phathom Pharmaceuticals Esperion Therapeutics (NASDAQ:ESPR) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability. Which has higher valuation & earnings, ESPR or SION? Esperion Therapeutics has higher revenue and earnings than Sionna Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEsperion Therapeutics$332.31M0.71-$51.74M-$0.80-1.49Sionna TherapeuticsN/AN/A-$61.69MN/AN/A Do analysts prefer ESPR or SION? Esperion Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 488.24%. Sionna Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 88.45%. Given Esperion Therapeutics' higher probable upside, equities research analysts clearly believe Esperion Therapeutics is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Esperion Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ESPR or SION more profitable? Sionna Therapeutics has a net margin of 0.00% compared to Esperion Therapeutics' net margin of -59.03%. Sionna Therapeutics' return on equity of 0.00% beat Esperion Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Esperion Therapeutics-59.03% -0.91% -29.47% Sionna Therapeutics N/A N/A N/A Do insiders and institutionals have more ownership in ESPR or SION? 47.4% of Esperion Therapeutics shares are held by institutional investors. 1.7% of Esperion Therapeutics shares are held by insiders. Comparatively, 3.9% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer ESPR or SION? In the previous week, Esperion Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 6 mentions for Esperion Therapeutics and 3 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.00 beat Esperion Therapeutics' score of 0.84 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Esperion Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryEsperion Therapeutics and Sionna Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Get Esperion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ESPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESPR vs. The Competition Export to ExcelMetricEsperion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$245.77M$2.50B$5.60B$9.10BDividend YieldN/A1.79%5.24%4.00%P/E Ratio-1.499.4227.9620.25Price / Sales0.71723.99429.2099.14Price / Cash51.61165.3637.4658.16Price / Book-0.604.608.045.49Net Income-$51.74M$31.26M$3.18B$250.27M7 Day Performance1.62%4.80%3.63%4.75%1 Month Performance-0.83%5.42%4.04%7.64%1 Year Performance-52.59%-4.36%29.56%16.34% Esperion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESPREsperion Therapeutics4.0385 of 5 stars$1.19-4.0%$7.00+488.2%-52.2%$245.77M$332.31M-1.49200News CoverageAnalyst RevisionSIONSionna TherapeuticsN/A$17.35+9.5%$38.50+121.9%N/A$765.48MN/A0.0035News CoverageQUREuniQure2.7195 of 5 stars$13.94+0.6%$37.82+171.3%+61.6%$763.63M$27.12M-3.18500AVBPArriVent BioPharma2.1309 of 5 stars$21.77-5.0%$40.00+83.7%+17.5%$744.75MN/A-5.7740Analyst UpgradeCRONCronos Group1.5793 of 5 stars$1.91+0.5%N/A-12.2%$736.65M$117.61M14.69450News CoverageXERSXeris Biopharma3.8729 of 5 stars$4.67-0.6%$6.25+33.8%+118.4%$730.30M$203.07M-15.57290News CoveragePHARPharming Group2.2567 of 5 stars$10.68-2.9%$30.00+181.0%+20.0%$726.29M$297.20M-53.38280Positive NewsGap DownHigh Trading VolumeREPLReplimune Group4.0843 of 5 stars$9.29-0.4%$20.83+124.3%+10.6%$716.17MN/A-3.03210News CoverageVIRVir Biotechnology3.6071 of 5 stars$5.04-2.5%$32.86+551.9%-38.3%$696.73M$74.21M-1.19580News CoverageAnalyst ForecastGYREGyre Therapeutics0.2315 of 5 stars$7.35-0.9%N/A-40.6%$689.14M$105.76M367.6840Positive NewsPHATPhathom Pharmaceuticals4.2116 of 5 stars$9.59-1.5%$17.50+82.5%-18.9%$669.48M$55.25M-1.83110 Related Companies and Tools Related Companies Sionna Therapeutics Competitors uniQure Competitors ArriVent BioPharma Competitors Cronos Group Competitors Xeris Biopharma Competitors Pharming Group Competitors Replimune Group Competitors Vir Biotechnology Competitors Gyre Therapeutics Competitors Phathom Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESPR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESPR Stock Alerts